Introduction: Oral daclatasvir (DCV; pangenotypic NS5A inhibitor) plus asunaprevir (ASV; NS3 protease inhibitor) is approved in Japan and Korea for treatment of chronic hepatitis C virus (HCV) genotype 1. Response to DCV ? ASV is affected by DCV resistanceassociated polymorphisms (RAPs) in HCV NS5A. The prevalence and influence of these RAPs on 12-week sustained virologic response (SVR12) to DCV ? ASV was evaluated in Asian and non-Asian patients. Methods: Data were pooled from 5 national and international studies of patients with HCV genotype 1b (GT-1b) receiving DCV ? ASV at their recommended doses. Baseline NS5A RAPs and their effect on SVR12 were assessed overall, in older (C65 years) patients, patients with cirrhosis, and in patients stratified by baseline HCV RNA or prior treatment experience with interferon-based therapy. Results: Baseline NS5A sequences were available from 988 patients (374 Japanese; 125 Korean/Taiwanese; 489 from non-Asian countries), 979 of whom were assessed for Electronic supplementary material The online version of this article (
SVR12. Pretreatment NS5A-L31F/I/M/V and/or NS5A-Y93H polymorphisms were present in 18% of Japanese and 12-13% of non-Japanese patients; these RAPs reduced SVR12 by 54.9% overall (93.9% [787/838] SVR12 when absent, 39.0% [55/141] SVR12 when present), with comparable reductions observed in Asians and non-Asians and across all categories of treatment experience, age, and cirrhosis. RAPassociated SVR12 rates declined with increasing baseline HCV RNA (SVR12 with RAPs: 64.7% [11/17] at 5-6 log 10 IU/mL, 29.8% [14/47] 
INTRODUCTION
Hepatitis C virus (HCV) is a highly polymorphic single-stranded RNA flavivirus that exists as 7 geographically diverse major genotypes with at least 67 subtypes [1] . Approximately, 80% of acute infections with HCV fail to clear spontaneously and progress to a state of chronic infection with serious long-term sequelae. It is estimated that within 20 years of infection, 60-70% of people with untreated chronic HCV infection will develop hepatic steatosis or fibrosis, up to 20% will develop cirrhosis, and up to 5% will progress to hepatocellular carcinoma [2] . Chronic HCV infection is estimated to be responsible for up to half a million liver-related deaths per annum [3] .
Treatment of HCV has evolved and improved remarkably in recent years. The ongoing introduction of all-oral combination regimens of direct-acting antiviral (DAA) agents has resulted in significantly shorter treatment durations, better tolerability, and higher rates of post-treatment sustained virologic response (SVR), a surrogate of cure, than earlier treatments based on the use of parenteral interferons. One such all-oral regimen combines daclatasvir (DCV)-a pangenotypic inhibitor of the multifunctional HCV NS5A nonstructural protein that is active in vitro against HCV genotype 1 (GT-1) through GT-6 [4]-with asunaprevir (ASV), an NS3 protease inhibitor with in vitro activity against HCV GT-1, GT-4, GT-5, and GT-6 [5] . In combination, treatment with these two agents has produced high rates of SVR among patients infected with the GT-1b subtype, including treatment-naïve patients, patients medically ineligible for-or intolerant of-peginterferon alfa and ribavirin (pegIFN/RBV), and patients who had previously not responded to or relapsed on pegIFN/RBV treatment [6] [7] [8] [9] [10] . The combination of DCV and ASV has been approved in Japan and Korea for the treatment of HCV genotype GT-1 and is currently under regulatory evaluation in other countries.
The HCV pandemic in Asia differs from that in the West in several ways that may impact response to DCV ? ASV or other new combinations of DAAs. Across much of Asia, the GT-1b subtype of GT-1 is the predominant HCV strain, whereas in North America and Northern Europe GT-1a is by far the most common [2] . The spread of HCV in Asia also predates that in North America and Western Europe, resulting in a significantly higher proportion of elderly patients in countries such as Japan and Taiwan than in most non-Asian countries, and a correspondingly higher incidence of cirrhosis and hepatocellular carcinoma [11] . Both older age and cirrhosis are historically associated with a higher burden of adverse events and poorer responses to interferon-based therapy [12, 13] , and their influence on response to newer oral regimens remains an area of great interest and research. Treatment-emergent NS5A variants associated with drug resistance and virologic failure have been described for DCV and other inhibitors of HCV NS5A, and these may exist pretreatment as naturally occurring resistanceassociated polymorphisms (RAPs) whose prevalence may vary by region and subtype. Treatment-emergent variants at NS5A amino acid positions 31 and 93 have been observed in both GT-1a and GT-1b virologic failures receiving DCV-containing regimens [14] [15] [16] [17] .
NS5A variants at these amino acid positions can also exist pre-therapy. In HCV GT-1binfected Japanese patients, pre-existence of NS5A RAPs at L31 or Y93H, as determined by a population-based direct sequencing approach, has impacted SVR to DCV ? ASV [17] . Two additional treatment-emergent NS5A variants at amino acid positions 28 and 30 have also been observed in patients with GT-1a virologic failure receiving DCV-containing regimens, which may also be present as RAPs at pretherapy baseline [14, 15] . 
Evaluations and Analyses
Baseline polymorphisms in HCV NS5A present in approximately 20% or more of the patients' virus population were assessed in each study by population-based sequencing as previously described [17] using the Con1 GT-1b consensus sequence as a reference (Accession number: AJ238799 Table 1 summarizes the 5 studies included in these pooled analyses and the number of patients from each who were included in the assessments of NS5A polymorphisms and SVR12 outcomes. In total, 988 patients were included in the full population, of whom 979 formed the SVR12 population. The 9 patients in the full population who were excluded from the SVR12 population comprised 2 patients (studies AI447-017 and AI447-028) who did not meet study criteria for resistance testing at failure due to having HCV RNA \LLOQ at their last visits; 2 patients (studies AI447-026 and AI447-028) who had requested that treatment be discontinued; 2 patients in AI447-028 who withdrew consent; 1 patient in AI447-028 who was lost to follow-up; and 2 patients in AI447-026 who discontinued therapy due to an adverse event. BL baseline, IFN interferon, RBV ribavirin a All enrolled in this category were null responders b Japan-only studies
RESULTS

Patient Demographics
The full population ( Table 2 ) comprised 296 treatment-naïve patients, 304 non-responders to pegIFN/RBV, 371 patients unable to be treated with pegIFN/RBV for reasons of intolerance or medical ineligibility, and 17 prior relapsers on pegIFN/RBV. There were 374 Japanese patients (37.9% of total), 63 Koreans (6.4%), 62 Taiwanese (6.3%), and 489 patients (49.5%) from non-Asian countries.
Prevalence of NS5A Polymorphisms
The prevalence of NS5A baseline polymorphisms in the full population is shown in Fig. 1 . With the exception of amino acid 31, polymorphisms at the positions of interest generally appeared to be more common among Asian than non-Asian HCV hepatitis C virus, IFN interferon, RBV ribavirin under 65 years), whereas the prevalence in older non-Asians (5.8%) was similar to or slightly lower than that in younger patients (7.4%).
Effect of NS5A Polymorphisms and Other Baseline Factors on SVR12
The association between baseline NS5A polymorphisms and SVR12 is shown in Fig. 2 for the full SVR12 population of 979 patients. baseline resulting in an overall 55% reduction in SVR12, from 94% to 39%. These data also established a higher prevalence of L31 or Y93H polymorphisms in the Japanese GT-1b population (18%) than in the non-Japanese patients (12-13%). This difference was driven by the prevalence of Y93H, which was twice as common among Japanese patients (15%) than those from non-Asian countries (7%), and 50% more common than among Asian patients from Korea and Taiwan (10%). The difference in Y93H prevalence between Japanese and other Asian patients was primarily due to a higher prevalence in Japanese patients under 65 years old than in younger Koreans and Taiwanese (13.6% versus 9.6%), but with an additional contribution from the higher proportion of older (C65 years) patients in the Japanese group (33%) compared to the non-Japanese Asians (25%) amongst whom the prevalence of Y93H was also higher (17.7% in older Japanese versus 12.9% in older Koreans and Taiwanese).
Interestingly, baseline polymorphisms at NS5A amino acid positions 28 or 30, previously associated with GT-1a virologic failures to DCV, were also twice as prevalent in both GT-1b Japanese and non-Japanese Asians (12%) compared with non-Asians (6%). However, these polymorphisms had no effect on SVR12 outcomes and therefore cannot be considered RAPs for GT-1b. The only baseline characteristic examined that had an effect on SVR12 independent of baseline NS5A RAPs was HCV RNA, where a small but continuous decline in SVR12 from 100% to 91% was evident across baseline strata ranging from \5 log 10 IU/mL to 7-8 log 10 IU/ mL. This was also the only baseline characteristic that appeared to show an interaction with the presence of NS5A RAPs.
In the absence of NS5A RAPs, a reduction in SVR12 rate of only 9% across all RNA strata was observed; however, in the presence of NS5A RAPs, reductions in SVR12 of approximately 50% were observed, with SVR12 rates ranging from 65% with a baseline viremia of 5-6 logs to 30% with 7-8 logs. The data suggest that the effects of NS5A-L31 and NS5A-Y93H polymorphisms on response to DCV ? ASV are partially mitigated by low baseline viremia.
It is relevant to note that reduced baseline susceptibility to DCV may also be mitigated by the composition of the DCV-containing regimen. Reduced HCV susceptibility at baseline to any given antiviral may in principle be compensated using that antiviral in combination with several non-cross-resistant agents, and/or in combination with potent agents with a high barrier to resistance. The significant predictive effect of NS5A L31 and Y93H RAPs on reduced response to DCV ? ASV shown here and in the data from Karino et al. [17] has not been apparent where DCV ? ASV is used in combination with the non-nucleoside NS5B-inhibitor beclabuvir (BCV), or in studies of DCV with the nucleotide NS5B-inhibitor sofosbuvir. In the UNITY-1 (ClinicalTrials.gov number, NCT01979939) [19] and UNITY-2 While there are many baseline factors that could influence sustained HCV responses to a given regimen, overall these data suggest that 
